Autopsy report · NCT02123576

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

“Poor enrollment of study population”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 9 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Patrick Northup, MD

Sponsor type

University, hospital or other

Conditions

Hepatorenal Syndrome

Interventions

Pentoxyfylline; Placebo; AMO Therapy

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography
  “Poor enrollment due to insufficient study support.” (82% match in meaning)
• Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults
  “Poor enrollment” (82% match in meaning)
• Prophylactic Phenobarbital After Neonatal Seizures
  “Inadequate rate of enrollment” (81% match in meaning)
• Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
  “Low study participant enrollment.” (80% match in meaning)
• Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide
  “Inability meet enrollment in study population.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.